What the FDA labels say about taking them together
Atazanavir and dolutegravir
Dolutegravir's FDA label of May 22, 2026 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name dolutegravir. The dolutegravir label: “Use of TIVICAY or TIVICAY PD with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY).
What does the atazanavir label say about dolutegravir?
Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name dolutegravir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the dolutegravir label say about atazanavir?
Dolutegravir label, drug interactionsConcomitant Drug Class/Drug Name: Non-nucleoside reverse transcriptase inhibitor: Etravirine a; Effect on Concentration of Dolutegravir and/or Concomitant Drug: ↓Dolutegravir; Clinical Comment: Use of TIVICAY or TIVICAY PD with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.
Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Dolutegravir | |
|---|---|---|
| Labeled for | HIV | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $77.64 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once